I Mab Stock In The News

IMAB Stock  USD 0.94  0.02  2.08%   
Our overall analysis of I Mab's news coverage and content from conventional and social sources shows investors' bearish mood towards I Mab. The specific impact of I Mab news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of I Mab's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using I Mab headlines in addition to utilizing other, more conventional financial analysis modules. Check out I Mab Backtesting and I Mab Hype Analysis.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.

I Mab Today Top News and Investor Outlook

Yahoo News
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
https://finance.yahoo.com/news/mab-appoints-phillip-dennis-md-110000252.html
 Bullish
Investors Business Daily at Macroaxis
Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%
https://finance.yahoo.com/news/individual-investors-account-41-mabs-144510638.html
 Bullish
Yahoo News
I-Mab Announces Participation at Jefferies and Piper Conferences in November
https://finance.yahoo.com/news/mab-announces-participation-jefferies-piper-130000024.html
 Bullish
reuters
BRIEF-Felzartamab Granted Breakthrough Therapy Designation by U.S. FDA for Primary Membranous Nephropathy
https://www.reuters.com/article/brief-felzartamab-granted-breakthrough-t/brief-felzartamab-granted-breakthrough-therapy-designation-by-u-s-fda-for-primary-membranous-nephropathy-idUSTUA2ST2PY
 Bullish
Yahoo News
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
https://finance.yahoo.com/news/felzartamab-granted-breakthrough-therapy-designation-120000144.html
 Bullish
Yahoo News
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
https://finance.yahoo.com/news/mab-announces-poster-presentations-4-120000465.html
 Neutral
Yahoo News
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
https://finance.yahoo.com/news/mab-announces-phase-1-data-120000352.html
 Bullish
Yahoo News
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
https://finance.yahoo.com/news/mab-abl-bio-announce-latest-120000342.html
 Bullish
Yahoo News
Ray Dalio on Potential US-China War and Rise of China
https://finance.yahoo.com/news/ray-dalio-potential-us-china-211726406.html
 Neutral
sbwire news
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
https://investorplace.com/2023/09/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-sept-28th/
 Bullish

I Mab Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide IMAB and other traded companies coverage with news coverage. We help investors stay connected with IMAB headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on IMAB Stock performance. Please note that trading solely based on the I Mab hype is not for everyone as timely availability and quick action are needed to avoid losses.
I Mab's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help I Mab investors visualize upcoming and past events in order to time the market based on I Mab noise-free hype analysis.
I Mab stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the IMAB earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about I Mab that are available to investors today. That information is available publicly through IMAB media outlets and privately through word of mouth or via IMAB internal channels. However, regardless of the origin, that massive amount of IMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of I Mab news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of I Mab relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to I Mab's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive I Mab alpha.

IMAB Largest EPS Surprises

Earnings surprises can significantly impact I Mab's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-06-02
2021-03-31-0.181-0.362-0.181100 
2023-08-17
2023-06-30-0.78-0.55640.223628 
2022-11-30
2022-09-30-0.2322-0.4644-0.2322100 
2022-08-30
2022-06-30-1.24-0.990.2520 
2023-03-31
2022-12-31-0.49-1.01-0.52106 
2020-12-02
2020-09-30-0.570.69731.2673222 
View All Earnings Estimates

I Mab Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to I Mab Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
21st of November 2024
I-Mab to Participate at the Piper Sandler Healthcare Conference
at finance.yahoo.com 
news
6th of November 2024
I-Mab Trading 3.7 percent Higher Heres Why
at thelincolnianonline.com 
news
30th of October 2024
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
at kalkinemedia.com 
Gurufocus Stories at Macroaxis
21st of October 2024
IMAB Stock Dips Over 5 percent Amidst Mixed Financial Performance
at gurufocus.com 
Google News at Macroaxis
23rd of September 2024
I-MAB Appoints New Board Member and Audit Committee - TipRanks
at news.google.com 
Yahoo News
16th of September 2024
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
29th of August 2024
I-MAB Q2 2024 Earnings Call Transcript Highlights Strategic Shifts and Financial Resilienc...
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards I Mab in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, I Mab's short interest history, or implied volatility extrapolated from I Mab options trading.
When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:
Check out I Mab Backtesting and I Mab Hype Analysis.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.16)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.29)
Return On Equity
(0.72)
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.